Spero Therapeutics

News

GSK will file oral carbapenem for complicated UTIs this year

GSK and Spero's cabapenem tebipenem is the first oral antibiotic in the class to show efficacy in complicated urinary tract infections.

News

Data sets up filing of new GSK antibiotic this year

GSK has said it will file its oral carbapenem antibiotic tebipenem HBr for approval before the end of this year as a treatment for complicated UTIs.

News

Helping to support momentum on antimicrobial innovation

Undeterred by FDA setback, GSK snaps up Spero antibiotic

GSK is paying $66 million upfront to license rights to Spero Therapeutics novel antibiotic tebipenem Hbr, unswayed by the FDA's decision earlier this year not to approve the drug for adults

News

FDA rejection of Spero's tebipenem 'raises resistance threat...

The FDA's decision not to approve Spero Therapeutics' oral antibiotic tebipenem Hbr for adults with complicated urinary tract infections (cUTI) further increases the threat of antibiotic re

GSK will file oral carbapenem for complicated UTIs this year

Data sets up filing of new GSK antibiotic this year

Undeterred by FDA setback, GSK snaps up Spero antibiotic

FDA rejection of Spero's tebipenem 'raises resistance threat...

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Spero Therapeutics

Editor's Picks